Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Last trade$18.12
Day change-$0.555 (-2.97%)
Day range$17.95 – $19.26
Volume638,826
Market cap$3.23B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.23B
Price / earnings
8.91×
Price / book
2.33×
Price / sales
2.68×
EV / sales
2.42×
EV / EBITDA
21.5×
Profitability
Earnings per share
$2.10
Return on assets
20.19%
Return on equity
26.11%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.82×
Quick ratio
3.7×
Cash ratio
0.97×
Cash flow
Price / cash flow
33.08×
Price / free cash flow
39.36×
Free cash flow
$81.99M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ACAD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$342.29M
$307.96M
$268.06M
$283.99M
$278.63M
$264.57M
$244.32M
$259.6M
Cost of revenue
$35.09M
$28.32M
$24.79M
$26.23M
$21.65M
$20.73M
$20.39M
$21.8M
Gross profit
$307.2M
$279.64M
$243.27M
$257.76M
$256.99M
$243.83M
$223.93M
$237.8M
Selling, general and administrative
$159.2M
$160.25M
$171.02M
$155.62M
$133.4M
$133.51M
$126.37M
$130.08M
Research and development
$76.28M
$81.56M
$76.87M
$84.76M
$87.83M
$77.95M
$78.27M
$100.73M
Total operating expenses
$235.48M
$241.81M
$247.89M
$240.37M
$221.23M
$211.46M
$204.64M
$230.81M
Operating income
$71.72M
$37.84M
-$4.62M
$17.39M
$35.76M
$32.37M
$19.29M
$6.99M
Interest expense
$8.42M
$0
$0
$0
$8.25M
$0
$0
$0
Income before taxes
$80.44M
$46.47M
$3.98M
$26.32M
$44.6M
$40.21M
$27.78M
$161.09M
Income taxes
$26.92M
$14.97M
$344K
-$247.25M
-$27.18M
$13.55M
$8.79M
$17.34M
Net income
$53.52M
$31.5M
$3.64M
$273.57M
$71.78M
$26.67M
$18.99M
$143.74M
Net income attributable to common shareholders
$53.52M
$31.5M
$3.64M
$273.57M
$71.78M
$26.67M
$18.99M
$143.74M
EBITDA
$80.82M
$35.55M
-$1.62M
$20.32M
$44.15M
$29.87M
$22.24M
$12.2M
Basic earnings per share
$0.31
$0.18
$0.02
$1.61
$0.43
$0.16
$0.11
$0.86
Diluted earnings per share
$0.31
$0.18
$0.02
$1.58
$0.42
$0.16
$0.11
$0.86
Recent news
Company coverage with links to the original publishers.
Viatris (VTRS) is expected to report Q3 2026 revenues of $3.78 billion and earnings of 64 cents per share, likely beating consensus estimates. The company faces headwinds from FDA import alerts affecting 11 products, supply disruptions, and competitive pressures, but these are expected to be offset by new product growth and strength in branded markets, particularly in Greater China and Emerging Markets.
Recursion Pharmaceuticals reported a Q3 loss of $0.22 per share, beating the consensus estimate of $0.24 loss, with an 8.33% earnings surprise. Revenue of $18.55 million surpassed estimates by 69.88%, up from $5.18 million year-over-year. The stock has underperformed the S&P 500 by 12.2% year-to-date and carries a Zacks Rank #3 (Hold) rating.
Acadia Pharmaceuticals is expected to report Q3 2026 earnings of $0.21 per share, representing a 19.2% year-over-year decline, despite revenues rising 20.2% to $334.87 million. With a negative Earnings ESP of -0.59% and Zacks Rank #3, the company is not considered a compelling earnings-beat candidate. However, Acadia has beaten consensus EPS estimates in 3 of the last 4 quarters, most recently delivering a +200% surprise.
Pomerantz LLP is investigating potential securities fraud claims against ACADIA Pharmaceuticals following disappointing Phase 3 trial results for remlifanserin announced on September 24, 2026. The drug narrowly missed its primary endpoint, causing ACAD stock to plummet 12.78% on the announcement day and an additional 6.76% the following day after analyst downgrades.
Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.